Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of “Buy” by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.50.

ATEC has been the topic of a number of research reports. Barclays reissued an “overweight” rating and set a $22.00 target price (up from $21.00) on shares of Alphatec in a report on Monday, August 4th. Lake Street Capital raised shares of Alphatec to a “buy” rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st.

Alphatec Trading Down 3.3%

Shares of ATEC stock opened at $15.80 on Friday. Alphatec has a twelve month low of $4.88 and a twelve month high of $16.70. The stock’s fifty day simple moving average is $13.58 and its 200 day simple moving average is $11.99. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm has a market capitalization of $2.34 billion, a P/E ratio of -13.98 and a beta of 1.02.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. During the same period last year, the firm posted ($0.29) earnings per share. The business’s revenue for the quarter was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alphatec will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Patrick Miles sold 300,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the completion of the sale, the chief executive officer directly owned 5,564,078 shares in the company, valued at $87,522,946.94. This represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Craig E. Hunsaker sold 10,876 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total transaction of $166,729.08. Following the completion of the transaction, the executive vice president owned 1,389,142 shares in the company, valued at approximately $21,295,546.86. The trade was a 0.78% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 506,284 shares of company stock valued at $7,579,535. Insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Alphatec

A number of large investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Alphatec by 301.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company’s stock valued at $608,000 after purchasing an additional 45,027 shares during the period. GAMMA Investing LLC raised its stake in Alphatec by 38,433.3% during the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock worth $228,000 after buying an additional 2,306 shares during the period. SG Americas Securities LLC raised its stake in Alphatec by 28.3% during the 1st quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company’s stock worth $577,000 after buying an additional 12,553 shares during the period. Oppenheimer Asset Management Inc. boosted its holdings in Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock worth $133,000 after acquiring an additional 1,552 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Alphatec by 6.9% in the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company’s stock valued at $1,508,000 after acquiring an additional 9,661 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.